高级检索

骨关节炎疾病改善型药物研究进展

Progress of research on disease-modifying osteoarthritis drugs

  • 摘要: 骨关节炎(OA)是一种常见的慢性关节疾病,主要的病理改变为关节软骨的退化和继发性骨质增生。现有的药物治疗方式存在明显的局限性,仅从镇痛角度治疗或行关节置换术,二者均不能从根本上改善关节软骨的病变。因此,抑制OA疾病进展的药物(DMOAD)应运而生。DMOAD通过参与调节软骨代谢平衡、参与软骨下骨重塑和控制局部炎症等机制从根本上抑制关节软骨结构性退变,从而使OA患者得到疼痛及功能的症状改善,延缓做人工关节置换术的时间,提高患者生活质量。目前全球范围内尚无DMOAD类药物上市,本文从DMOAD药物的研发背景、作用机制以及各类机制下在研代表药物的研发进展进行综述,为今后的研究提供参考。

     

    Abstract: Osteoarthritis (OA) is a common chronic joint disease,whose main pathological changes are the degeneration of articular cartilage and secondary bone hyperplasia.The limitation of current treatment methods including pain relief and joint replacement surgery is that they cannot fundamentally improve the damage of articular cartilage.The emergence of disease-modifying osteoarthritis drugs (DMOAD) may break the above limitations.They fundamentally inhibit the structural degeneration of articular cartilage by participating in the regulation of cartilage metabolic balance, regulation of subchondral bone remodeling,and control of local inflammation.Thereby,OA patients will get symptom improvement including pain relief and joint function restoration,delay the artificial joint replacement surgery, and improve the quality of life. There are still no DMOAD drugs widely available on the market worldwide.This paper reviews the background of R&D,the classification of mechanisms of action and research progress of representative drugs under different inechanisms so as to provide reference for future research.

     

/

返回文章
返回